A M Thi1, H D Shewade2, N T T Kyaw1, M M Oo1, T K Aung1, S T Aung3, H N Oo4, T Win5, A D Harries6. 1. International Union Against Tuberculosis and Lung Disease (The Union), Mandalay, Myanmar. 2. The Union, South-East Asia Office, New Delhi, India. 3. National Tuberculosis Programme, Ministry of Health, Nay Pyi Taw, Myanmar. 4. National AIDS Programme (NAP), Ministry of Health, Nay Pyi Taw, Myanmar. 5. NAP, Ministry of Health, Mandalay, Myanmar. 6. The Union, Paris, France ; London School of Hygiene & Tropical Medicine, London, UK.
Abstract
SETTING: Integrated HIV Care programme, Mandalay, Myanmar. OBJECTIVES: To determine time to starting antiretroviral treatment (ART) in relation to anti-tuberculosis treatment (ATT) and its association with TB treatment outcomes in patients co-infected with tuberculosis (TB) and the human immunodeficiency virus (HIV) enrolled from 2011 to 2014. DESIGN: Retrospective cohort study. RESULTS: Of 1708 TB-HIV patients, 1565 (92%) started ATT first and 143 (8%) started ART first. Treatment outcomes were missing for 226 patients and were thus not included. In those starting ATT first, the median time to starting ART was 8.6 weeks. ART was initiated after 8 weeks in 830 (53%) patients. Unsuccessful outcome was found in 7%, with anaemia being an independent predictor. In patients starting ART first, the median time to starting ATT was 21.6 weeks. ATT was initiated within 3 months in 56 (39%) patients. Unsuccessful outcome was found in 12%, and in 20% of those starting ATT within 3 months. Patients with CD4 count <100/mm(3) had a four times higher risk of an unsuccessful outcome. CONCLUSIONS: Timing of ART in relation to ATT was not an independent risk factor for unsuccessful outcome. Extensive screening for TB with rapid and sensitive diagnostic tests in HIV-infected persons and close monitoring of anaemia and immunosuppression are recommended to further improve TB treatment outcomes among patients with TB-HIV.
SETTING: Integrated HIV Care programme, Mandalay, Myanmar. OBJECTIVES: To determine time to starting antiretroviral treatment (ART) in relation to anti-tuberculosis treatment (ATT) and its association with TB treatment outcomes in patients co-infected with tuberculosis (TB) and the human immunodeficiency virus (HIV) enrolled from 2011 to 2014. DESIGN: Retrospective cohort study. RESULTS: Of 1708 TB-HIVpatients, 1565 (92%) started ATT first and 143 (8%) started ART first. Treatment outcomes were missing for 226 patients and were thus not included. In those starting ATT first, the median time to starting ART was 8.6 weeks. ART was initiated after 8 weeks in 830 (53%) patients. Unsuccessful outcome was found in 7%, with anaemia being an independent predictor. In patients starting ART first, the median time to starting ATT was 21.6 weeks. ATT was initiated within 3 months in 56 (39%) patients. Unsuccessful outcome was found in 12%, and in 20% of those starting ATT within 3 months. Patients with CD4 count <100/mm(3) had a four times higher risk of an unsuccessful outcome. CONCLUSIONS: Timing of ART in relation to ATT was not an independent risk factor for unsuccessful outcome. Extensive screening for TB with rapid and sensitive diagnostic tests in HIV-infectedpersons and close monitoring of anaemia and immunosuppression are recommended to further improve TB treatment outcomes among patients with TB-HIV.
Entities:
Keywords:
HIV-associated TB; SORT IT; adverse TB treatment outcomes; early ART initiation; operational research; treatment outcome
Authors: M Maruza; M F P M Albuquerque; M C Braga; M T S Barbosa; R Byington; I Coimbra; L V Moura; J D L Batista; G T N Diniz; D B Miranda-Filho; H R Lacerda; L C Rodrigues; R A A Ximenes Journal: Int J Tuberc Lung Dis Date: 2012-03-08 Impact factor: 2.373
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Serena P Koenig; Cynthia Riviere; Paul Leger; Patrice Joseph; Patrice Severe; Kea Parker; Sean Collins; Erin Lee; Jean W Pape; Daniel W Fitzgerald Journal: Clin Infect Dis Date: 2009-03-15 Impact factor: 9.079
Authors: Anna Odone; Silvia Amadasi; Richard G White; Theodore Cohen; Alison D Grant; Rein M G J Houben Journal: PLoS One Date: 2014-11-12 Impact factor: 3.240
Authors: Swe Swe Thit; Ne Myo Aung; Zaw Win Htet; Mark A Boyd; Htin Aung Saw; Nicholas M Anstey; Tint Tint Kyi; David A Cooper; Mar Mar Kyi; Josh Hanson Journal: BMC Med Date: 2017-08-04 Impact factor: 8.775